Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in metastatic colorectal cancer after standard therapy
CTR20131659Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regorafenib in metastatic colon cancer (mCRC), sponsored by Bayer. Started Jun 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20131659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131659.